Intensity Therapeutics Inc

Research Intensity Therapeutics Inc (INTS) on Bullrun: market cap USD 10.25M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerINTS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 10.25M
• Financial periodFY2025
• Net income-USD 11.61M

Valuation Snapshot

latest market cap is USD 10.25M.

About Intensity Therapeutics Inc

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Frequently asked questions

What is Intensity Therapeutics Inc's market cap?

Intensity Therapeutics Inc's market capitalization is USD 10.25M.

What does Intensity Therapeutics Inc do?

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.